Trial · NCT06128967
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
NCT06128967, Phase 3, Completed, Cardresearch
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial. Trials, record NCT06128967. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06128967
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
- NCT number
- NCT06128967
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 399 participants, actual
- Lead sponsor
- Cardresearch
- Conditions
- Long COVID-19 Syndrome, Chronic Fatigue Syndrome
- Interventions
- Fluvoxamine Maleate 100 MG, Placebo, Metformin Extended Release Oral Tablet
- First posted
- 2023-11-13
- Last updated
- 2026-04-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement on Fatigue Severity Score Scale (FSS) | Day 60 after randomization | Improvement on Fatigue Severity Score Scale (FSS) |
| Secondary | Improvement on Fatigue Severity Score Scale (FSS) | Day 30 after randomization | Improvement on Fatigue Severity Score Scale (FSS) |
| Secondary | Improvement on Fatigue Severity Score Scale (FSS) | Day 30 post Study Drug Termination (Day 90 after randomization) | Improvement on Fatigue Severity Score Scale (FSS) |
| Secondary | Reduction on any cause hospitalization | Day 60 after randomization | Reduction on any cause hospitalization |
| Secondary | Safety of metformin | Since randomization up to Day 60 (last IMP dose) | Safety of metformin (intention to treat analysis) |
| Secondary | Safety of Fluvoxamine | Since randomization up to Day 60 (last IMP dose) | Safety of Fluvoxamine (intention to treat analysis) |
| Secondary | Death of any cause | Since randomization up to Day 60 (last IMP dose) | Occurrence of Death of any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06128967
GET https://conductscience.org/api/trials/v1/NCT06128967/registered